Company:Pharmacyclics
| Type | Subsidiary |
|---|---|
| NASDAQ: PCYC | |
| Industry | Biopharmaceutical |
| Founded | 1991 |
| Founders | Jonathan Sessler, Richard A. Miller[1] |
| Headquarters | Sunnyvale, California |
Area served | Worldwide |
Key people | Robert Duggan, former CEO and Chairman |
| Revenue |  US$235 million (2013)[2] |
| US$110 million (2013)[2] | |
| US$86.1 million (2013)[2] | |
| Total assets | US$1.06 billion (2013)[2] |
| Total equity | US$829 million (2013)[2] |
| Parent | AbbVie |
| Website | pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies.[3][4] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.[5]
Acquisition by AbbVie
In March 2015, Chicago -based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity.[6] The merger is expected to close in mid-2015.[7]
Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."[8][9][10][11][12]
As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.[8]
References
- ↑ Lee Clippard (2006). "Professor's personal battle leads to development of new cancer drug". University of Texas. http://www.ti3d.utexas.edu/news-events/professors-personal-battle-leads-to-development-of-new-cancer-drug.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Shangri-La Hotels and Resorts Annual report 2019-20". Shangri-La Hotels and Resorts Asia. https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0427/2020042701439.pdf.
- ↑ Sawyer, Anthony (25 January 2018). "Pharmacyclics (PCYC) Given Daily Media Impact Score of 0.42". Week Herald. https://weekherald.com/2018/01/25/pharmacyclics-pcyc-given-daily-media-impact-score-of-0-42.html.
- ↑ "Pharmacyclics Inc. (PCYC)". Yahoo. https://finance.yahoo.com/q/pr?s=PCYC.
- ↑ "Xynomic Acquires Global Rights to Anticancer Drug Abexinostat". Genetic Engineering & Biotechnology News. February 24, 2017. http://www.genengnews.com/gen-news-highlights/xynomic-acquires-global-rights-to-anticancer-drug-abexinostat/81253930.
- ↑ Staff (5 March 2015). "AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B". Genetic Engineering & Biotechnology News. http://www.genengnews.com/gen-news-highlights/abbvie-acquires-oncology-drug-firm-pharmacyclics-for-21b/81250997/.
- ↑ "Ex-99.1". https://www.sec.gov/Archives/edgar/data/949699/000119312515079014/d885940dex991.htm.
- ↑ 8.0 8.1 Gary Strauss (March 24, 2015). "The $3.55 billion Man". USA Today. http://americasmarkets.usatoday.com/2015/03/24/the-3-55-billion-man/.
- ↑ Antoine Gara. "Robert Duggan". Forbes. https://www.forbes.com/profile/robert-duggan/.
- ↑ "Pharmacyclics May Soon Be Acquired by Johnson & Johnson for $18 Billion". Science Times. 3 March 2015. http://www.sciencetimes.com/articles/3458/20150303/pharmacyclics-may-soon-be-acquired-by-johnson-johnson-for-18-billion.htm.
- ↑ "The Hiring Guru: Robert Duggan Billionaire". The Huffington Post. 18 April 2014. http://www.huffingtonpost.com/david-jensen/the-hiring-guru-robert-du_b_5164474.html.
- ↑ Sean Williams (27 February 2013). "This Is One Incredible CEO". fool.com. http://www.fool.com/investing/general/2013/02/27/this-is-one-incredible-ceo-19.aspx.
External links
- Business data for Pharmacyclics:
- SEC filings
 |
